Oruka Therapeutics (ORKA) Non-Current Deffered Revenue (2010 - 2018)
Oruka Therapeutics' quarterly Non-Current Deffered Revenue came in at $4000.0 in Q3 2018, down 84.0% year-on-year from $25000.0 in Q3 2017, and down 55.56% quarter-over-quarter from $9000.0 in Q2 2018.
Oruka Therapeutics has reported Non-Current Deffered Revenue for 9 years, with the latest figure at $4000.0 in Q3 2018.
- For the quarter ending Q3 2018, Non-Current Deffered Revenue fell 84.0% year-over-year to $4000.0; the trailing twelve-month figure through Sep 2018 stood at $4000.0 (down 84.0% YoY), and the FY2017 full-year result was $20000.0, down 48.72% from the prior year.
- Non-Current Deffered Revenue for Q3 2018 stood at $4000.0, down from $9000.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $47000.0 in Q2 2016, with the low at $1000.0 in Q1 2014.
- Average Non-Current Deffered Revenue over 5 years is $17375.0, with a median of $12000.0 recorded in 2018.
- Year-over-year, Non-Current Deffered Revenue slumped 87.5% in 2014 and surged 4600.0% in 2016.
- Tracing ORKA's Non-Current Deffered Revenue over 5 years: stood at $3000.0 in 2014, then slumped by 66.67% to $1000.0 in 2015, then soared by 3800.0% to $39000.0 in 2016, then tumbled by 48.72% to $20000.0 in 2017, then tumbled by 80.0% to $4000.0 in 2018.
- The last three Non-Current Deffered Revenue figures came in at $4000.0 (Q3 2018), $9000.0 (Q2 2018), and $15000.0 (Q1 2018), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Oruka Therapeutics | 3.04 Bn | 2.65 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 4,000.00 |
| Jun 30, 2018 | 9,000.00 |
| Mar 31, 2018 | 15,000.00 |
| Dec 31, 2017 | 20,000.00 |
| Sep 30, 2017 | 25,000.00 |
| Jun 30, 2017 | 30,000.00 |
| Mar 31, 2017 | 35,000.00 |
| Dec 31, 2016 | 39,000.00 |
| Sep 30, 2016 | 43,000.00 |
| Jun 30, 2016 | 47,000.00 |
| Jun 30, 2015 | 1,000.00 |
| Mar 31, 2015 | 1,000.00 |
| Dec 31, 2014 | 3,000.00 |
| Sep 30, 2014 | 3,000.00 |
| Jun 30, 2014 | 2,000.00 |
| Mar 31, 2014 | 1,000.00 |
| Dec 31, 2013 | 1,000.00 |
| Jun 30, 2013 | 3,000.00 |
| Mar 31, 2013 | 8,000.00 |
| Dec 31, 2012 | 16,000.00 |
| Sep 30, 2012 | 24,000.00 |
| Jun 30, 2012 | 33.00 Mn |
| Mar 31, 2012 | 8,000.00 |
| Dec 31, 2011 | 16,000.00 |
| Sep 30, 2011 | 25,000.00 |
| Jun 30, 2011 | 32,000.00 |
| Dec 31, 2010 | 195,000.00 |